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Molecular autopsy of a lethal Spitzoid melanoma
G Hosler,2,1 EE Lee,1 B Litzner,1 P Kapur,3 R Rapini,5 T Davoli4 and RC Wang1 1 Dermatology, 
UT Southwestern Medical Center, Dallas, TX, 2 Dermatopathology, ProPath, Dallas, TX, 3 
Pathology, UT Southwestern Medical Center, Dallas, TX, 4 Elledge Lab, Harvard Medical 
School, Boston, MA and 5 Dermatology, UT Houston, Houston, TX
On December 2005, a 19 year old patient was diagnosed with a 1.6mm Spitzoid melanoma. Despite 
complete excision and negative sentinel lymph node biopsy, the patient passed away from wide-
spread metastatic disease to her brain less than 8 years later. We performed a targeted molecular 
analysis of both the primary tumor and the first brain metastasis using the following studies: fluores-
cence in situ hybridization (FISH) for CCND1, CDKN2A, cMyc, and RREB1; immunohistochemistry 
(IHC) for BRAFV600E mutation and BAP1; and Sanger sequencing of the TERT promoter. Based on 
these data and current models of melanoma carcinogenesis, we propose a possible sequence of 
events for the molecular insults that gave rise to this deadly Spitzoid melanoma. In addition, survival 
analyses on specific mutated pathways are presented. This case report highlights the importance 
of several known pathways in the pathogenesis of melanoma and suggests that further studies are 
necessary to determine the prognostic significance of these pathways in early cutaneous melanoma.   
LB793
NS2, a novel aldehyde trap, decreases aldehyde levels in dry skin and eye models
SL Young,1 TC Brady,1 E Perez2 and JR Fernandez2 1 Aldeyra Therapeutics, Inc., Burlington, 
MA and 2 Signum Dermalogix, Inc., Monmouth Junction, NJ
Free aldehydes are naturally occurring chemical species formed during a variety of biological 
processes, including polyamine and glucose metabolism and lipid peroxidation. Uncontrolled 
levels of aldehyde species can lead to inflammation via activation of the NF-κβ pathway and also 
damage key lipids that comprise the dermal moisture barrier and lubricate the surface of the eye. 
Elevated levels of malondialdehyde (MDA) have been shown in a variety of inflammatory skin and 
eye diseases, including psoriasis, atopic dermatitis, anterior uveitis, and ocular rosacea. In addition, 
high levels of fatty aldehydes in Sjögren-Larsson Syndrome, an orphan disease caused by mutations 
in fatty acid aldehyde dehydrogenase, lead to severe ichthyosis, retinal disease and neurological 
disorders. Here, we report the effect of dry conditions on inducing MDA levels in human skin and 
eye tissue and the activity of NS2, a novel aldehyde-binding small molecule, in reducing levels of 
MDA generated by dry conditions. Topical application of NS2 cream to three-dimensional human 
skin equivalents lowered MDA levels (measured by TBARS assay) induced by dry skin conditions. 
Moreover, topical application of NS2 eye drops to three-dimensional human cornea-like tissue 
lowered MDA levels induced by dry eye conditions. These results suggest that NS2 could mitigate the 
toxic aldehyde load that is generated in dry skin and dry eye conditions. By trapping aldehydes, NS2 
may protect skin and eye tissue from chronic inflammation caused by aldehydes that are generated 
in dry conditions, and in addition may protect lipids that are critical in preserving moisture in skin 
and eye. Thus, NS2 represents a potential novel compound that could provide a dual benefit to 
individuals with dry skin or dry eyes.    
LB794
Sorghum extract as an active cosmetic ingredient
WP Smith,1 J Gulley,1 G Mola,2 N Alminana2 and R Delgado2 1 Active Organics, Lewisville, 
FL and 2 Lipotec SAU, Barcelona, Spain
Sorghum is an important drought resistant food grain grown throughout the world. It is rich in 
polyphenols, flavonoids and condensed tannins with anti-oxidant activity which has been found 
to correlate with an anti-hyaluronidase activity. Protection of hyaluronic acid from breakdown by 
UV and inflammatory reactions will minimize negative transient and cumulative changes in skin 
quality. We have developed a polyphenol-rich Sorghum product via water-glycerin extractions and 
have documented in vivo and in vitro bio-effects. At 3% Sorghum reduced by more than 40% the 
intensity and duration of neural sensory irritation (NSI) induced by 12% lactic acid application to 
the nasal fold area. A single application of 3% Sorghum reduced methyl nicotinate (MN) induced 
NSI and skin inflammatory response by about 40%. With repeat applications (5 days, twice a day) 
the concentration of MN required to induce a visible skin reaction more than doubled. Sorghum also 
visibly reduced the inflammatory reactions induced by topical application of a variety of contact irri-
tants. Pilot clinical studies on Eczema and Atopic Dermatitis revealed a number of subjects showed 
dramatic improvements after repeated treatment with 3% Sorghum. In vitro studies demonstrated: 
Sorghum inhibited the PAR-2 evoked interleukin-8 release in Primary Human Epidermal Kerati-
nocytes by about 20%. Sorghum significantly reduced the damaging potential of the superoxide 
radical, the hydroxyl radical and the peroxyl radical, all important contributors to skin aging via UV 
exposure and endogenous irritant reactions. In vitro and in vivo testing has established Sorghum’s 
effectiveness as a treatment for inflammatory skin reactions.    
LB795
Effect of new extract of yeast on strengthening dermal matrix ex vivo and reducing appear-
ance of wrinkles in vivo
L Mur, Y Ferreira, G Oberto, C Coquet-Morel, V Lequoy, C Gondran, K Cucumel and 
N Domloge Vincience, Ashland Specialty product, Sophia Antipolis, France
The dermis and its structure provide some primary skin properties such as strength, elasticity and 
density. To assume this role, fibroblasts produce and maintain the scaffold of extracellular matrix 
(ECM) by synthesizing different macromolecules and smaller proteins that play a key role in matrix 
organization; among them, dermatopontin, distributed on the surface of collagen fibers. Dermato-
pontin regulates collagen fibrillogenesis, by allowing the formation of homogeneous collagen fibrils. 
The aim of our study was to evaluate the effect of a new extract from yeast on the expression of 
DPT and key dermal proteins in in vitro and ex vivo experiments. Dermal protein expression was 
assessed by immuofluorescence stainings. Paxillin and actin network were visualized on dermal 
fibroblasts in culture. The results showed a positive modulation of dermatopontin, collagen I and 
paxillin in ex vivo skin treated with the extract. The staining of paxillin appeared also more intense 
in treated fibroblast cultures. Moreover, we observed a more developed network of elastic fibers in 
the papillary dermis of treated biopsies compared to placebo. In vivo study was conducted on the 
face of 14 volunteers for a four-week period. The anti-wrinkle property of the extract was evaluated 
by the analysis of silicone replicas done on the crow’s feet and by color pictures. This study showed 
a significant reduction in the appearance of the number, as well as the average length and depth 
of wrinkles, after 28 days of treatment, compared to placebo treated sides. Furthermore, these 
beneficial effects on appearance of wrinkles were visible on color pictures and by trained expert 
evaluation. The ex vivo results indicated that the positive modulation of dermatopontin and other 
ECM components was associated with an abundant ECM secretion, inducing a strengthening of 
collagen and elastic fibers. In addition, in vivo studies revealed the correlation between application 
of the extract and reduction in the appearance of wrinkles.    
LB796
Elevated circulating cardiovascular risk markers in psoriasis patients are diminished by sys-
temic treatment but not by narrowband UVB therapy
G Sigurdardottir,1 A Ekman,1 C Bivik,1 M Ståhle2 and C Enerbäck1 1 Ingrid Asp Psoriasis 
Research Center, Linköping University, Linköping, Sweden and 2 Unit of Dermatology and 
Venereology, Karolinska Insitutet, Stockholm, Sweden
Psoriasis patients display an elevated risk of cardiovascular disease which may be linked to a sys-
temic inflammation and the increased frequency of the metabolic syndrome in this patient group. 
The aim of the study was to investigate the circulating levels of cardiovascular risk markers in pso-
riasis patients and to evaluate how these markers are affected by UVB therapy and treatment with 
a systemic TNF-α inhibitor. Six markers of cardiovascular risk- soluble vascular adhesion molecule 
(sVCAM)-1, soluble intercellular adhesion molecule (sICAM)-1, soluble (s)E-selectin, myeoloperox-
idase (MPO), matrix metalloproteinase (MMP)9 and total plasminogen activator inhibitor (tPAI)-1- 
were selected and measured systemically in psoriasis patients. The relationship between the levels 
of these markers and the body mass index (BMI) and the waist-hip ratio (WHR) was studied in a 
matched population. The markers were quantitated before and after treatment with UVB therapy or 
with the TNF-α inhibitor etanercept. Psoriasis patients displayed increased circulating levels of five 
of the six measured markers. Of these, sICAM-1, sE-selectin, MMP9 and tPAI-1 correlated to the BMI 
and WHR, suggesting a link to the metabolic syndrome. tPAI-1 remained elevated independently 
of these factors. Treatment with TNF-α inhibitor reduced the circulating levels of the investigated 
risk markers, while the markers remained unaffected by UVB therapy. These findings suggest that 
the choice of treatment in psoriasis may influence the cardiovascular risk in patients with psoriasis 
and the metabolic syndrome.    
LB797
Nonhealing diabetic foot ulcers: A disease of the dermal lymphatics
LA Wold Rosalind Franklin University, North Chicago, IL
The purpose of this study is to determine the underlying characteristic amongst patients with dia-
betic foot ulcers (DFUs) who fail to show ulcer improvement despite treatment with hyperbaric 
oxygen therapy (HBOT). Literature comparing patient characteristics with outcome of HBOT in the 
treatment of DFUs was scrutinized. Patients with basal transcutaneous oxygen pressure (bTcPO2) 
< 25 mm, nephropathy (dialysis or renal transplant patients), and smokers with a > 40 pack year 
history show significantly lower rates of healing. TcPO2 is a measurement of the functional status 
of the microvasculature near the ulcer. Nephropathy is a known consequence of diabetic micro-
angiopathy, a consistent morphologic feature of diabetes with a high prevalence for renal and 
dermal capillaries. Smoking increases risk of microvascular disease in diabetics despite intensive 
insulin therapy. All three attributes are physiologically tied to the microvasculature. Alternatively, 
characteristics reflecting macrovasculature show no correlation with HBOT outcome, including ABI, 
TBP, neuropathy, and peripheral arterial disease. Recent research shows a rich network of blood 
vessels supplies lymphatic vessels. The high oxygen requirement of lymphatic cells is due to their 
contractility, which is necessary to clear excess fluid and allow for wound healing. Diabetics with 
microvessel disease likely lack a functioning capillary network to supply the lymphatics, which 
would result in edema, increased diffusion distances within the skin, and poor wound healing. 
Studies show that HBOT effectively induces angiogenesis and lymphangiogenesis. Furthermore, 
patients successfully treated with HBOT have intact microvasculature with bTcPO2 > 25 mm and 
have functioning lymphatics in the affected limb evident in the reduction in limb edema after 
treatment. The literature shows that chronic diabetes impairs angiogenesis and damages the archi-
tecture of existing capillaries. In conclusion, efforts are needed to assess the microvasculature and 
lymphatics of the skin surrounding DFUs in the context of HBOT outcome to help clarify the type 
of patient that would benefit from HBOT.    
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Nonsense mutation in y-secretase gene, NCSTN, causing autosomal dominant hidradenitis 
suppurativa in an African-American family
PL Mattei,1 S Chen,1 J You,2 N Sobreira2 and GA Hinds1 1 Dermatology, Johns Hopkins 
School of Medicine, Baltimore, MD and 2 Genetic Medicine, Johns Hopkins School of 
Medicine, Baltimore, MD
Hidradenitis suppurativa (HS) is a chronic disease characterized by the formation of painful, sup-
purative and scarring nodules often affecting intertriginous areas. The y-secretase genes NCSTN, 
PSENEN, and PSEN1 have been identified in autosomal dominant forms of HS in 2 British, 5 Chinese, 
1 Japanese, and 3 French families. Our proband was a 45-year-old African American female with 
HS onset at age 15. Her BMI was 28 and she had never smoked. She had history of acne, hirsutism, 
and pilonidal cysts and her groin was most severely affected. She was Hurley stage 2, had a Sartorius 
score of 98 and a DLQI score of 18 at the time of sequencing. Her family history is extensively 
significant for HS with four affected generations including 9 affected individuals. Informed consent 
was obtained from all subjects. DNA was isolated from venous blood. We performed whole exome 
sequencing of the proband and used the PhenoDB analysis tool to search for mutations. Upon finding 
a mutation, we used Sanger sequencing to identify the mutation in affected and unaffected family 
members. Whole exome sequencing of the proband using the PhenoDB analysis tool identified 
a heterozygous nonsense mutation in exon 4 of NCSTN (c.C349T; p.R117X). Sanger sequencing 
identified this same mutation in 5 other affected family members and did not identify the mutation 
in 2 unaffected individuals. This mutation was not identified in the dbSNP, Exome Variant Server, 
1000 Genome Database or among our internal controls. To date, 17 cases of mutations in NCSTN 
have been described in individuals with HS; 3 of them were nonsense mutations in Chinese and 
French families. Based on the truncating nature of this rare variant, and the family segregation, we 
suggest that this case is the first description of an NCSTN nonsense mutation causing autosomal 
dominant HS in an African-American family.    
LB799
Agouti signalling protein (ASIP) acts as an inverse agonist to the melanocortin-1 receptor 
(MC1R) in the wild type grey squirrel (S. carolinensis) and as agonist to the melanic variant 
(MC1RΔ24)
HR McRobie, LM King and P Coussons Life Sciences, Anglia Ruskin University, Cambridge, 
United Kingdom
Melanism in the grey squirrel (Sciurus carolinensis), is associated with an eight amino acid deletion 
in the melanocortin-1 receptor (MC1R). This G protein- coupled receptor, expressed in melano-
cytes, is a key regulator of mammalian pigmentation. In mice, the MC1R is activated by its agonist, 
alpha-melanocyte-stimulating hormone (α-MSH) and inactivated by its inverse agonist, agouti sig-
nalling protein (ASIP). MC1R activation stimulates eumelanogenesis by raising intracellular cAMP 
levels via coupling to adenylate cyclase; inactivation stimulates a switch to phaeomelanogenesis. 
This study aimed to elucidate the function of the wildtype MC1R (MC1R-wt) compared to mutant 
MC1R (MC1RΔ24) found in melanic squirrels in order to understand the molecular basis of melanism 
in the grey squirrel. We compared the cAMP response of cells transfected with either MC1R-wt or 
MC1RΔ24 stimulated with α-MSH or ASIP. The MC1R-wt showed an α-MSH-mediated concen-
tration-dependent increase in intracellular cAMP. In parallel experiments, the MC1RΔ24 showed 
an elevated basal level of intracellular cAMP and a response to α-MSH. The MC1R-wt showed an 
ASIP-mediated concentration-dependent decrease in intracellular cAMP. In contrast, the MC1RΔ24 
showed an ASIP-mediated concentration-dependent increase in intracellular cAMP. Concentrations 
of α-MSH and ASIP varied from 0nM-100,000nM. Structural models predict that the eight amino acid 
deletion in MC1RΔ24 causes the first extracellular loop to be shorter in the mutant. This deletion 
may mimic agonist binding and cause a conformational change of the intracellular region in the 
MC1RΔ4 leading to a constitutively active receptor. The shorter loop may prevent ASIP acting as an 
inverse agonist. We conclude that MC1RΔ24 is constitutively active, producing a higher basal level 
of intracellular cAMP compared to the MC1R-wt and that ASIP acts as an inverse agonist to MC1R-wt 
but as an agonist to MC1RΔ24. This is the first study to report ASIP acting as an agonist to the MC1R.   
LB800
Combined treatment with arsenic trioxide and itraconazole inhibits the Hedgehog pathway 
in patients with refractory metastatic basal cell carcinoma: Results from a pilot trial
M Rezaee,1 MS Ally,1 K Sarin,1 S Atwood,2 AS Chang,1 A Oro,1,2 I Bailey,1 D Colevas3 and 
JY Tang1 1 Dermatology, Stanford University, Redwood City, CA, 2 Stanford University 
School of Medicine, Stanford, CA and 3 Cancer Center, Stanford University, Stanford, CA
Aberrant Hedgehog (HH) signaling causes basal cell carcinoma (BCC). The oral HH-inhibitor, vis-
modegib, is successful in treating locally advanced and metastatic BCCs (mBCC) by antagonizing 
SMO, a key transducer of HH signaling, however resistance is common. Itraconazole and arsenic 
trioxide (ATO) have been shown to inhibit HH signaling at sites distinct from other SMO inhibitors. 
Our primary goal was to assess whether combined ATO and itraconazole can reduce HH signaling 
in patients with metastatic BCCs that have failed SMO inhibitors. The secondary objectives include 
evaluation of tumor response and tolerability during 3 months of therapy. We enrolled 5 patients 
with mBCC in a proof-of-concept phase II trial and treated them with ATO (0.30 mg/kg IV for 5 
days, every 28 days) for a total of 3 cycles. Oral itraconazole 400 mg daily was given between 
ATO cycles. We compared mRNA levels of the HH-pathway target gene, GLI1, in skin biopsies 
pre and post-treatment. Three patients completed 3 cycles of treatment; two discontinued early 
due to disease progression and treatment-related adverse events. Side effects included grade 1/2 
fatigue, lymphocytopenia and transaminitis. Overall, ATO/itraconazole reduced GLI1 mRNA by 
75% from baseline (p<0.0001). Four of five patients had evaluable tumor by RECIST criteria. The 
best overall response after 3 cycles was stable disease in 3 patients and progressive disease in 1 
patient. In conclusion, combined ATO/itraconazole can inhibit HH-pathway activity however, 
some patients experienced no growth of tumor (stable disease for 3 months) but none had tumor 
shrinkage. This trial demonstrates the feasibility of targeting the HH pathway by ATO/itra, our next 
trial will test higher doses or continuous dosing schedules to fully inhibit the HH pathway which 
may yield better clinical response.    
LB801
Multiple dominant T-cell clones and increased disease severity in cutaneous T-cell lymphoma
T Sun,1 E Martinez-Escala,1 J Gao,2 S Rosen3 and J Guitart1,3 1 Dermatopathology, 
Northwestern University, Chicago, IL, 2 Pathology, Northwestern Memorial Hospital, 
Chicago, IL and 3 Hematooncology, Robert H. Lurie Cancer Center, Chicago, IL
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of lymphomas with widely varied 
severity and progression. Previous studies used Multiplex GeneScan PCR to detect pathogenic T-cell 
clones from CTCL lesions, and several descriptive studies suggested that patients with one dominant 
T-cell clone that is reproducible at the lesion site and in either blood or lymph node have more severe 
disease than those without a reproducible T-cell clone in at least 2 sites (Vega F, et al. Blood 2002, 
Fierro M, et al. J Invest Dermatol 2010). Here, we used the established T-cell clonality detection 
method to investigate associations between the presence of dominant T-cell clones and disease 
stage at presentation, disease progression, and response to therapy in a large cohort of 265 CTCL 
patients. Contrary to the prior reports, our study revealed that 2 or more dominant T-cell clones is 
associated with increased disease severity and refractoriness to treatment, whereas one dominant 
T-cell clone is not significantly different from no dominant clones. We further observed that many 
patients have small reproducible T-cell clones that are detectable but below the current established 
threshold for clonality. These small clones may become dominant over the course of treatment as the 
major clones are targeted (Papalas J, et al. Leukemia & Lymphomas 2011), leading to progressive or 
refractory disease. Our data thus suggest that early aggressive therapy may be considered for CTCL 
patients with two or more dominant T-cell clones. Moreover, the current guidelines for detecting 
T-cell clones in CTCL should be revisited so that patients who are likely to have a more progressive 
course of disease can be identified early and treated appropriately    
LB802
Day treatment regimen for the management of recalcitrant generalized prurigo nodularis: A 
neglected therapy offers new promise
E Sorenson,1 E Levin2 and J Koo2 1 Keck School of Medicine of the University of Southern 
California, Los Angeles, CA and 2 Dermatology, University of California, San Francisco, San 
Francisco, CA
The objective of this case series was to evaluate the effectiveness of a modified Goeckerman regimen 
in managing four cases of recalcitrant generalized prurigo nodularis (PN). The regimen consisted 
of daily stepwise broadband ultraviolet B (UVB) phototherapy followed by topical application of 
crude coal tar 2-10% and topical corticosteroids under occlusion each day. The average patient 
age was 52.3 years (range 15 – 68 years) and one patient had chronic hepatitis B. All patients had 
previously failed therapy with clobetasol 0.05% ointment and either broadband UVB (2 patients) or 
narrowband UVB phototherapy (2 patients). The mean course of therapy with the modified regimen 
was 45.5 days (range 29 – 70 days), and the mean total broadband UVB exposure was 11,827.5 
mJ (range 3480 – 26,250 mJ) to the extremities, the body area receiving the greatest exposure for 
all patients. The only adverse events experienced were mild phototoxic reactions that were easily 
managed by reducing the broadband UVB dose. Within 2 weeks, all patients demonstrated marked 
improvement of pruritis, and by the completion of therapy all patients demonstrated complete or 
nearly complete flattening of nodules. Goeckerman therapy has previously been reported to be an 
effective treatment for psoriasis and atopic dermatitis. Although generalized PN is often a highly 
challenging condition to treat, a modified Goeckerman regimen provided safe and effective treat-
ment for four patients with recalcitrant generalized PN.    
LB803
Cascade regulation of sweat gland development by Wnt, Eda and Shh pathways
C Cui, M Yin, J Sima, V Childress, M Michel, Y Piao and D Schlessinger National Institute 
on Aging, Baltimore, MD
To maintain body temperature, millions of sweat glands develop from embryonic ectoderm by a 
poorly defined mechanism. We present evidence for a temporal cascade of regulation of sweat 
gland development by Wnt, Eda and Shh pathways. The first stage, sweat gland induction, failed 
completely when Wnt/β-catenin signaling was blocked in skin epithelium, and was accompanied 
by sharp downregulation of downstream Wnt, Eda and Shh pathway genes. In a meta-layer of reg-
ulation, Wnt antagonist Dkk4 appeared to operate on sweat gland induction in a negative feedback 
loop: Dkk4 was sharply downregulated in β-catenin-ablated mice, indicating that it is induced by 
Wnt/β-catenin; but its overexpression repressed Wnt target genes and significantly reduced gland 
numbers. Eda signaling succeeded Wnt. Thus, in absence of Eda, Wnt signaling was still active and 
nascent sweat gland pre-germs were seen but failed to develop further; and the downstream Shh 
pathway was not activated. When Wnt and Eda were intact but Shh was ablated, germ induction and 
subsequent duct formation occurred normally, but the final stage of secretory coil formation failed. 
Thus, sweat gland development shows a relay of regulatory steps, initiated by Wnt/β-catenin — itself 
modulated by Dkk4 — with subsequent participation of Eda and Shh pathways.    
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Acral melanocytic lesions in two metropolitan areas in the United States
PV Gumaste,1 PR Schaffer,1 S Choudhary,2 L Falto-Aizpurua,2 S Damanpour,2 S Patel,2 
M Sanchez,2 H Arora,2 H Kanavy,3 M Sanchez,1 D Polsky,1 JM Grichnik2 and JA Stein1 1 The 
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, 
New York, NY, 2 Dermatology, University of Miami, Miami, FL and 3 Dermatology, St. 
Barnabas Medical Center, New York, NY
The frequency and dermoscopic patterns of acral melanocytic lesions have not been investigated in 
the United States, particularly in an ethnically-diverse patient population. Additionally, the utility of 
screening acral melanocytic lesions for the early detection of acral lentiginous melanoma is unclear. 
We prospectively examined the palms and soles of patients presenting to general dermatology clinics 
in New York City and Miami. A closed-question survey was administered prior to examination to 
evaluate for personal or family history of melanoma, Fitzpatrick skin-type, ethnic background, and 
awareness of acral pigmented lesions. There were 300 patients included in this study. Patients with 
skin-of-color comprised a majority of our study cohort (Hispanic: 43%, Black: 14%, Asian: 12%). 
A total of 157 acral pigmented lesions (acquired nevi: 57%, congenital nevi: 33%, lentigines: 10%) 
were observed in 99 of the 300 patients (33%). Increased arm nevi density was associated with the 
presence of an acral melanocytic lesion in white, non-Hispanic patients, but not in skin-of-color 
patients (p=0.076). The most common dermoscopic patterns observed on the palms were parallel 
furrow (56%), lattice-like (10%), homogenous (6%), and crista-dotted (6%). On the soles, the most 
common dermoscopic patterns were parallel furrow (33%), lattice-like (19%), and fibrillar (10%). 
Of note, only 19 of 61(31%) patients were aware they had a pigmented lesion on their sole. With 
respect to pigmented lesions on the palm, only 20 of 59 (34%) patients were aware that a lesion 
was present. The preliminary results of our study suggest that although acral melanocytic lesions are 
relatively common, patients are generally not aware of these lesions. Patients should be counseled 
to monitor their palms and soles for clinically suspicious lesions.    
LB805
Topical delivery of a potent and selective RORγ inhibitor abrogates Th17 cytokines from 
human skin resident immune cells
SH Smith,1 CE Peredo,1 Y Takeda,2 K Richter,1 T Bui,1 J Neil,1 H Aloor,1 B Millerman,1 
J Therrien,1 E Nicodeme,3 J Brusq,3 F Viviani,3 H Hofland,1 A Jetten2 and J Cote-Sierra1 1 
Stiefel, GSK, Research Triangle Park, NC, 2 NIEHS, NIH, Research Triangle Park, NC and 3 
FDU, GSK, Les Ulis, France
Psoriasis is a chronic inflammatory skin disorder involving marked inflammatory changes, including 
the expression of Th17 cytokines (IL-17A, IL-17F and IL-22). Recently, the central role of IL-17 to 
psoriasis was validated with biologics, where the systemic neutralization of IL-17 family cytokines 
resulted in a significant improvement in clinical measures. The transcription factor RORγt has been 
described as the master regulator for IL-17 production and is therefore considered a prime target for 
therapeutic treatment. As such, inhibitors of RORγt have gained significant interest as potential ther-
apeutics. Herein we describe a novel, potent and highly selective inverse agonist small molecule for 
RORγ/RORγt, termed GSK Compound A (GSK A), that significantly inhibits Th17 cytokine production 
in multiple assay systems. In accordance with the central role of RORγ to Th17 cytokines, GSK A 
dramatically suppresses transcript levels of Th17-type cytokines when applied to a mouse model of 
psoriasis. Likewise, GSK A shows dose dependent cytokine suppression in activated peripheral blood 
T cells. To assess GSK A potency in a human system relevant to psoriasis, a novel tissue-based assay 
focusing on skin-resident immune responses was developed. In this model system, resident T cells 
are activated in situ in freshly excised healthy human skin, resulting in Th17 type cytokine produc-
tion that can be markedly inhibited by GSK A in the culture medium. Moreover, when formulated 
for topical delivery, GSK A penetrates the skin barrier to inhibit RORγ, resulting in profound IL-17 
suppression. Based on these data, it is expected that topical delivery of this RORγ-specific inverse 
agonist will impact local cytokine expression, leading to improved clinical outcome in patients.   
LB806
Statin use is associated with increased risk of non-melanoma skin cancer: Prospective results 
from the Women’s Health Initiative
A Wang,1 J Kubo,1 M Stefanick,1 M Desai,1 JE Manson,2 H Strickler,3 LW Martin,4 
J Wactawski-Wende,5 M Simon6 and JY Tang1 1 Stanford University School of Medicine, 
Stanford, CA, 2 Harvard Medical School, Boston, MA, 3 Albert Einstein College of Medicine, 
Bronx, NY, 4 George Washington University, Washington DC, DC, 5 University of Buffalo, 
Buffalo, NY and 6 Karmanos Cancer Institute, Detroit, MI
The relationship between statin use and non-melanoma skin cancer (NMSC) is unclear with few pro-
spective studies. Laboratory research has suggested both protective and detrimental effects of statin 
use on NMSC risk, and statins carry a photosensitivity warning. We investigated this relationship 
among postmenopausal non-Hispanic white women in the prospective Women’s Health Initiative 
(WHI) cohort, which enrolled women aged 50-79 years from 1993-1998 at 40 U.S. centers. Among 
161,808 participants, 120,292 women with no cancer history at baseline (excluding skin cancer) 
and complete medication/covariate data comprised the analytic cohort. The association of NMSC 
incidence and statin use (baseline, duration, type, potency, lipophilicity) was determined using 
logistic regression models. Over 10.5 mean follow-up years, 12,156 NMSC cases were identified. 
Compared to women with no statin use, use of any statin at baseline was associated with significantly 
increased NMSC incidence (ORadj 1.18, 95% CI 1.05-1.33). In particular, lovastatin (OR 1.58, 
1.11-2.24), simvastatin (OR 1.41, 1.15-1.73), and lipophilic statins (OR 1.32, 1.12-1.56) were all 
associated with increased NMSC risk. Low and high, but not medium, potency statins were asso-
ciated with higher NMSC incidence. Longer statin use duration was not associated with increased 
NMSC risk. No significant effect modification of the statin-NMSC relationship was found for age, 
BMI, smoking, solar irradiation (Langleys), Vitamin D use, and skin cancer history. In conclusion, 
our results suggest that statin use, particularly lipophilic statins, may increase NMSC risk. As new 
cholesterol guidelines may broaden statin use, understanding of its effect on NMSC risk will help 
inform prevention and treatment approaches.    
LB807
Increasing growth factor bioavailability in complex biological fluids by hydrated polyure-
thanes – implications for wound healing
H Smola,1,2 G Maier,2 M Junginger,2 M Kettel2 and S Smola3 1 Dept. of Dermatology, 
University of Cologne, Cologne, Germany, 2 Paul Hartmann AG, Heidenheim, Germany and 
3 Dept. of Virology, Saarland University, Homburg, Germany
Cutaneous tissue repair is a highly coordinated cellular process. During inflammation, granulation 
tissue formation and epithelial wound closure the different cell types interact via diffusible growth 
factors. Exogenous application of growth factors has been explored. An alternative strategy aims 
to increase the bioavailability of endogenous growth factors contained in the wound exudate. We 
here analyzed the potential of hydrated polyurethanes (PU) which in contrast to conventional 
polyurethane foam wound dressing contain large amounts of water. Hydrated polyurethanes were 
generated by different combinations of polyetherpolyol (Jeffamine), propylenglycol and isocyanate. 
This produced soft, clear, water-containing gels which can be molded into slab dressings. These 
polymers can swell and absorb fluids. We tested the absorption capacity with tissue culture medium 
containing 5% serum as surrogate for wound fluid. For functional studies Hepatocyte Growth Factor 
(HGF) was spiked to the artificial wound fluid. After 18 hours, the PU-gels absorbed from 0.995 ml/g 
(35,6% polymer content, PC) to 1.176ml/g (31,7% PC) decreasing to 1.119 ml/g (31,3% PC). Total 
protein in the supernatant above the PU gels increased to 171% (35,6% PC) to 180% (34,2% PC) 
decreasing to only 127% (31,3% PC) when compared to the start. Spiked HGF increased to from 
20 ng/ml to 63 ng/ml + 1.9 ng/ml after 24 hours absorption and with a 1.8 ratio (v/w) of medium 
to gel. In scratch assays with HaCaT keratinocytes HGF reduced the scratch wound to 69% + 10% 
of controls (without PU-gel absorption) to 26.2% + 8.6% (after PU-gel absorption; p=<0,001). 
These results indicate that hydrated polyurethane can enhance epithelial wound closure. In acute 
as well as chronic wounds when normal wound healing mechanisms are reactivated by correct-
ing the underlying pathology hydrated polyurethanes can be beneficial by increasing the relative 
concentration of growth factors.    
LB808
In vitro study demonstrating nail penetration of tavaborole from tavaborole topical solution, 
5% through multiple layers of nail polish
B Elewski,3 D Coronado,2 S Chanda,2 T Merchant,2 H Lin,2 L Zane2 and T Vlahovic1 1 Temple 
University School of Podiatric Medicine, Philadelphia, PA, 2 Anacor Pharmaceuticals, Inc, 
Palo Alto, CA and 3 Department of Dermatology, University of Alabama, Birmingham, AL
PURPOSE: To evaluate the effect of nail polish application practices on the nail penetration of 
Tavaborole Topical Solution, 5%. METHODS: Human cadaver fingernails from eight female donors 
were mounted on Vertical Diffusion Cells and were randomized to four groups representing different 
application practices (for each, N=7). One nail from each donor was dosed unpainted. Groups 1 and 
2 each had one coat of a salon and a home use brand, respectively, Group 3 had two coats of home 
polish, Group 4 had a base coat, two coats of salon polish and a final clear coat. Tavaborole Topical 
Solution, 5% was applied daily (25 mL/cm2) to each nail for 14 days. Nail penetration was measured 
by monitoring the tavaborole concentration in the receiving medium. RESULTS: After 14 days, the 
mean (SD) cumulative penetration of tavaborole through nails in Groups 1 and 2 were 1,227 (974) 
mg/cm2 and 1,428 (841) mg/cm2, respectively, Group 3 was 1,493 (1,322) mg/cm2 and Group 4 
was 1,179 (554) mg/cm2, and through unpainted nails was 566 (318) mg/cm2. CONCLUSION: 
Tavaborole from Tavaborole Topical Solution, 5% can penetrate through four layers of nail polish.   
LB809
Tavaborole: The first benzoxaborole compound investigated for the treatment of onychomy-
cosis represents a new class of antifungal agents with a unique mechanism of action
J Del Rosso,1 L Kircik,2 J Plattner,3 T Rosen,4 L Zane3 and F Rock3 1 Las Vegas Skin & Cancer 
Clinics, Las Vegas, NV, 2 DermResearch, PLLC, Louisville, KY, 3 Anacor Pharmaceuticals, Inc, 
Palo Alto, CA and 4 Michael E. DeBakey VA Medical Center, Houston, TX
PURPOSE: To describe the unique mechanism of action (MOA) of tavaborole, a small boron-based 
molecule with broad spectrum antifungal activity and a high level of nail penetration. METHODS: 
Tavaborole is a benzoxaborole compound with high water solubility and potent antifungal activity 
needed to treat onychomycosis. It effectively penetrates the nail plate after topical application. As 
Trichophyton rubrum is refractory to most genetic techniques, Saccharomyces cerevisiae was used 
to determine the tavaborole MOA in vivo. Characterization of tavaborole-resistant mutant yeast 
mapped mutations to a CDC60 gene that codes for the cytoplasmic enzyme leucyl-tRNA synthetase 
(LeuRS). This and biochemical characterization permitted identification of the inhibitory MOA of 
tavaborole in susceptible fungi. RESULTS: Aminoacyl-tRNA synthetase (AARS) comprise a family of 
enzymes that play a pivotal role in protein synthesis. Cytoplasmic leucyl-tRNA synthetase (LeuRS) 
is an AARS. These enzymes play a pivotal role in maintaining and translating genetic code within 
DNA. LeuRS possess an editing mechanism that corrects enzymatic mistakes and occurs on a 
separate editing site. Tavaborole targets fungal cytoplasmic LeuRS by binding to the editing site 
together with tRNA. There, tRNA is trapped preventing further cellular protein synthesis resulting 
in fungal growth inhibition. Tavaborole has high fungal specificity with low affinity for mammalian 
AARS. This MOA is novel among currently available antifungal agents and tavaborole is the first 
in the benzoxaborole class submitted for FDA approval. CONCLUSION: The MOA of tavaborole 
is distinct from imidazole, triazole, allylamine, and benzylamine antifungal compounds which 
block ergosterol synthesis and differs from other AARS inhibitors by binding to the editing domain. 
Tavaborole is in a new antifungal agent with a unique MOA.    
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DRP1 serine 616 phosphorylation: A potential biomarker for BRAFV600E melanoma devel-
opment and treatment
SY Wieder,1,2,6 MN Serasinghe,1,2,4 J Yao,2,3 J Spivack5 and JE Chipuk1,2,4 1 Oncological 
Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 2 Dermatology, Icahn 
School of Medicine at Mount Sinai, New York, NY, 3 Dermatopathology, Icahn School of 
Medicine at Mount Sinai, New York, NY, 4 Tisch Cancer Institute, Icahn School of Medicine 
at Mount Sinai, New York, NY, 5 Health Evidence and Policy, Icahn School of Medicine at 
Mount Sinai, New York, NY and 6 Albert Einstein College of Medicine, Bronx, NY
DRP1 (dynamin related protein-1) is a pro-fission mitochondrial dynamics protein that is activated 
by phorphorylation at serine 616. Previous investigations implicate DRP1S616 in oncogenic MAPK 
signaling and inhibition. We hypothesize that DRP1S616 phosphorylation may contribute to the 
progression of benign nevus to melanoma and in clinical responses to targeted therapies. We 
use immunofluorescence and immunohistochemistry techniques on cellular and tissue models of 
BRAFV600E melanoma to evaluate this hypothesis. Results indicate that small molecule inhibition of 
BRAFV600E leads to a significant reduction of DRP1S616 phosphorylation levels in melanoma cell lines. 
In primary melanoma tissues, a significant positive association is observed between BRAFV600E and 
DRP1S616 phosphorylation status (p<0.001). This positive association is also observed in BRAFV600E 
nevi. As the molecular determinants that define the progression from benign nevus to melanoma 
remain unclear, we propose that DRP1S616 phosphorylation status may serve as a valuable biomarker 
for malignant transformation of melanocytes and can potentially be used to distinguish good from 
poor responders to targeted therapies.    
LB811
Evaluating immortalized human dermal papilla as an in vitro model for hair biology
T Dicolandrea, H Matheny, P Hu and CC Bascom Life Sciences TPT, Procter & Gamble, 
Mason, OH
Hair dermal papilla (DP) cells are specialized mesenchymal cells which regulate hair formation, 
growth, and cycling. Maintenance of signaling from DP is known to control the length of anagen, in 
vivo. Using DP cells for the development of predictive assays for hair benefits has been difficult in 
the past, in part due to the inability of normal DP cells to retain key behaviours of DP in vivo. We 
have attempted to address this outage by creating immortalized DP cell lines that display several 
aspects of the hair-inductive DP in vivo. Tert-DP can spontaneously form spheroid structures remi-
niscent of dermal papilla in vivo. The formation of these structures can be modulated by pinacidil, 
vitamin D and minoxidil hair growth agents. These forming structures begin to express hair-cycling 
and dermal condensation associated genes compared against 2D cell cultures. The induction of 
alkaline phosphatase (AP) activity is a biomarker which heralds the movement of the hair follicle 
from telogen to anagen, and is decreased only as the hair moves from anagen to the resting phase of 
catagen. We show that our immortalized cells retain AP activity and can be induced to increase AP 
activity in the presence of biologic modifiers of hair growth. Thus we believe that our immortalized 
dermal papilla cell lines can be used to develop predictive assays for hair benefits by measuring 
the induction of AP activity.    
LB812
Diacerein inhibits pro-inflammatory and atherogenic effects of IL-1α in primary keratinocytes 
and endothelial cells
G Mohan,1 L Bao1 and LS Chan1,2 1 Dermatology, UIC College of Medicine, Chicago, IL and 
2 Medicine, JBVA Medical Center, Chicago, IL
Psoriasis is an inflammatory skin disease in which IL-1 is known to play a key role. It is also known 
that psoriasis has significant cardiovascular co-morbidity. We investigated how IL-1α impacts 
epidermal inflammation and vascular atherosclerosis on a cellular level and whether diacerein, 
known as an IL-1β inhibitor, could also reverse IL-1α’s effects. Primary human keratinocytes (KC) 
and human coronary artery endothelial cells were either treated with IL-1α alone, both IL-1α and 
diacerein, or left untreated, for 24 hours. Using reverse transcription-PCR method, the mRNA levels 
of several genes were measured. In KC’s, pro-inflammatory genes such as IL1F9, CXCL2 and DEFB4 
were significantly up-regulated when treated with IL-1α. This effect was completely reversed by 
diacerein. Using an inflammatory response/autoimmunity PCR microarray, we assessed a broader 
spectrum of differential gene expression regulated by IL-1α and diacerein. In KC’s, we identified 
25 genes that were at least 2-fold up-regulated by IL-1α with p-value<.05. BMP7, CXCR3, IL9 and 
TNFSF18 were most affected at 1087, 988, 755 and 39-fold up-regulation, respectively. Diacerein 
completely or partially reversed the up-regulation of all 25 genes, significantly (p<.05) in 23 of them, 
including CXCL2, CXCR3, IL9, PTAFR and TLR3. Interestingly, we also observed that diacerein 
significantly (p<.05) down-regulated 44 other inflammatory genes not altered by IL-1α, including 
CCL26, TNF and VEGFB by 40, 4 and 2-fold respectively. Thus, diacerein provides an innate 
anti-inflammatory effect in KC’s. Similar to the inhibitory effect diacerein had on KC inflammatory 
gene expression, diacerein showed significant (p<.05) inhibition of several atherosclerosis-related 
genes that were up-regulated by IL-1α in endothelial cells, such as ICAM1 and SELE. These data offer 
cellular evidence that IL-1α may play an important role in skin inflammation and atherosclerosis 
in psoriasis and also support a novel idea that diacerein acts as an inhibitor of the epidermal and 
vascular effects of IL-1α.    
LB813
Association of vitiligo and alopecia areata with atopic dermatitis: A meta-analysis
G Mohan and J Silverberg Dermatology, Northwestern University, Chicago, IL
Previous studies explored the relationship between alopecia areata (AA), vitiligo and atopic derma-
titis/eczema (AD) with conflicting results. Predictors for the co-occurrence of AA or vitiligo with AD 
were not determined due to limited statistical power. We performed a systematic literature search 
and meta-analysis on AA, vitiligo and AD. We searched the Medline, Embase and Cochrane library 
databases and 13 journals. Odds ratios (OR) and 95% confidence intervals (CI) were estimated by 
the Cochrane-Mantel-Haenszel method. We selected 13 studies of the association of AD with vit-
iligo, including 6534 patients from 10 countries, and 11 studies of AD with AA, including 794,421 
patients from 8 countries. Overall, 767 (11.7% [0.8–47.6%]) of vitiligo patients and 1198 (12.4% 
[3.3–32.3%]) of AA patients had a previous or current history of AD. Patients with vitiligo (pooled 
OR [95% CI]:3.18 [2.14–4.72], P<0.001) and AA (2.57 [2.25–2.94], P<0.001) had significantly 
higher odds of AD. There was greater heterogeneity in the prevalences of AD in studies of vitiligo 
than in studies of AA. Sensitivity analyses found significant differences of effect size by study region, 
but no differences for dermatologist diagnosis vs. self-report of AD or for old vs. young age of onset 
of vitiligo or AA. In conclusion, AD appears to be associated with increased risk of vitiligo and 
AA, which suggests common genetic, inflammatory and/or behavioral factors. Further research is 
needed to determine the mechanism of association between these disorders.    
LB814
Psoriasin contributes to stress-induced angiogenesis in psoriasis
J Vegfors, C Bivik, A Ekman and C Enerbäck Ingrid Asp Psoriasis Research Center, 
Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
Psoriasin, S100A7, is highly expressed in psoriasis. Vascular modifications occur early in the devel-
opment of the psoriasis plaque and angiogenesis is one of the key features in the pathogenesis of 
the disease. This study aims to define the angiogenic properties of psoriasin and investigate the 
direct effects on dermal derived endothelial cells that promote angiogenesis in psoriasis. Psoriasin 
expression was found to be induced by hydrogen peroxide (H2O2) in keratinocytes as well as 
by the cellular stress factors hypoxia and cobalt chloride (CoCl2), both known to induce H2O2. 
Down-regulation of psoriasin expression, by siRNA, decreased the H2O2-induced expression of 
vascular endothelial growth factor (VEGF), heparin-binding EGF-like growth factor (HB-EGF), matrix 
metalloproteinase (MMP)-1 and MMP-9, and counteracted the H2O2-mediated reduction of the 
anti-angiogenic factor thrombospondin (THBS)-1, demonstrated by qPCR. Extracellular adminis-
tered psoriasin was found to induce proliferation, migration and tube formation of dermal derived 
endothelial cells, demonstrated by in vitro angiogenesis assays. Furthermore, inhibition of the 
phosphoinositide-3-kinase (PI3K) and nuclear factor (NF)-κB signalling pathways in endothelial 
cells suppressed the psoriasin-induced migration. In conclusion, psoriasin is induced by cellular 
stress conditions and regulates H2O2-induced expression of angiogenic factors in keratinocytes. 
Moreover, psoriasin mediates the angiogenic process by inducing proliferation, migration and tube 
formation of dermal derived endothelial cells. Altogether, our findings demonstrate that psoriasin 
is a contributor to stress-induced angiogenesis and has a potent pro-angiogenic activity on dermal 
derived endothelial cells, affecting several steps of the angiogenic process in vitro.    
LB815
Cryptomphalus aspersa mollusk eggs extract promotes migration and regenerative behavior 
of human keratinocytes and mesenchymal stem cells in vitro
J Espada,1 N Salazar,1 A Damián,1 A Cifuentes,2,3 N García-Honduvilla,2,3 E Reyes,4 
M Álvarez-Mon,2 M Buján,2,3 S Gonzalez5 and A Juarranz1 1 Dept. of Biology, Faculty of 
Sciences, Univ. Autonoma de Madrid, Madrid, Spain, 2 Dept. of Medicine and Medical 
Specialties, Faculty of Medicine, Univ. de Alcalá, Alcalá de Henares, Spain, 3 Networking 
Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, 
Spain, 4 Industrial Farmacéutica Cantabria, SA, Madrid, Spain and 5 Dermatology Service, 
Memorial Sloan-Kettering Cancer Center, New York, NY
Skin aging is a progressive loss of cell functions influenced by the combination of endogenous 
and exogenous factors, mostly ultraviolet light (UV) exposure. In this study we evaluate the in 
vitro effects of a new product derived from the eggs of Cryptomphalus aspersa (IFC-CAF) on cell 
physiology of keratinocytes (HaCaT cells) and mesenchymal stem cells (MSCs), and on cell pro-
tection against UV-induced damage. Several techniques have been used, such as MTT assay, flow 
cytometry, wound-healing assay, western blot and ELISA. We have found that IFC-CAF has no 
effects on HaCaT cells proliferation, while it diminishes MSCs proliferation. Interestingly, IFC-CAF 
induces a more keratinocyte-like polyhedral morphology in both cell types and a larger and more 
basophile cytoplasm, reflecting a higher cell metabolism which is consistent with an increase in 
the number of cells in the S phase of the cell cycle, as proven in HaCaT cells. It also stimulates 
the migratory behavior of HaCaT cells by promoting the expression of vinculin, increasing their 
wound healing potential. In addition, IFC-CAF shows protective properties by reducing the levels 
of UVB-induced H2AX activation and decreasing the basal levels of metalloproteinase 9. Finally, 
IFC-CAF triggers the differentiation of MSCs to a skin-like cell lineage, as demonstrated by the 
induction of the expression of cytokeratin 14, a specific marker of keratinocytes from the basal 
membrane. Thus, IFC-CAF promotes protective and regenerative pathways and could prevent or 
delay photoaging-related processes.    
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The role skin dendritic cells in nanoparticle transport and the induction of contact hyper-
sensitivity response (CHS)
S Jatana1 and LA DeLouise1,2 1 Biomedical Engineering, University of Rochester, Rochester, 
NY and 2 Dermatology, University of Rochester, Rochester, NY
Langerhans cells (LCs) play a key role in developing immune tolerance to UVR that protects us from 
developing polymorphous light syndromes. Although the widely used immunologic mouse model 
of Contact Hypersensitivity (CHS) using chemical allergens demonstrates the suppressive effect of 
UVR, what the model lacks is the role of NPs in altering antigen presentation and immune tolerance. 
We questioned whether skin dendritic cells can transport nanoparticles (NP) from the skin to the 
lymph nodes following a topical application. Towards this aim, Quantum Dots (QDs-Cadmium 
Selenide core) were topically applied on the back of SKH-1 hairless mice following UVR exposure 
(180 mJ/cm2) at day 0, day 4 and day 7 post-irradiation. After the 24 hour QD application the 
tissues (skin, lymph nodes, spleen, liver, heart, intestines) were analyzed using Atomic Absorption 
Spectroscopy (AAS) for the presence of Cadmium (Cd). We recovered 60% of the total Cd in all 
the tissues analyzed and 38% of the total recovered Cd was present in the skin with no significant 
differences between the treatment groups. A small amount of Cd was detected in the lymph nodes 
with an increase in Cd levels at day 7 post irradiation. To further verify which specific cells were 
involved in QD transport from the skin to the lymph nodes we performed flow cytometric analysis on 
the axillary, brachial, cervical and inguinal lymph nodes. We observed colocalization of QDs with 
dendritic cells (MHCII+), macrophages (CD68+) and CD207+ LCs. QD colocalization with LCs was 
also observed in histological sections of skin both in the case of topical application and intradermal 
injection (positive control). Our findings demonstrate that cellular transport of nanoparticles from 
the skin following topical application is one of the possibilities and these nanoparticles may lead to 
the induction of CHS. Studies are underway to test the hypothesis that NPs combined with chemical 
haptens will generate immunogenic epitopes that can modulate CHS and UV Treg generation.   
LB817
Improved clinical and quality of life assessments for moderate to severe atopic dermatitis 
in children with S. aureus colonization after daily cleansing with a uniquely-formulated 
sodium hypochlorite gel
B Bohaty,1 K Durham,1 G Abramovici,2 DP West,2 AA Hebert1 and AS Paller2 1 Department 
of Dermatology, The University of Texas Health Science Center at Houston, Houston, TX 
and 2 Department of Dermatology, Northwestern University Feinberg School of Medicine, 
Chicago, IL
Children with atopic dermatitis (AD) colonized by Staphylococcus aureus (S. aureus) suffer from 
frequent disease exacerbations. Dilute sodium hypochlorite (bleach) baths have been established 
as a method to decrease AD severity. This trial evaluated the improvement in moderate-to-severe 
S. aureus colonized children who used a uniquely formulated sodium hypochlorite (0.006%) anti-
microbial gel wash once daily. Subjects were recruited from two urban, academic-based pediatric 
dermatology clinics in the U.S. Upon confirmation of cutaneous S. aureus colonization, assessments 
occurred at 3 visits over a 6-week period and included Eczema Area and Severity Index (EASI), 
Investigator Global Assessment (IGA), and Pruritus Visual Analog Scale (VAS) to assess response 
in this open-label trial. Forty subjects (63% male and mean age = 8.5±9.0 yrs) had a mean change 
from baseline in IGA at 2 and 6 wks of 0.9±0.9 (22.8% improved; P<.00001) and 1.2±1.1 (33.8% 
improved; P<.00001), respectively. Mean change in EASI score was 4.8±6.9 at 2 wks (34.3% 
improved; P<.0001) and 6.2±8.1 at 6 wks (43.8% improved; P<.0001). Mean change in VAS was 
2.4±2.9 (31.2% improved; P<.00001) at 2 wks and 2.7±3.2 (36.8% improved; P<.00001) at 6 wks. 
Use of this user-friendly delivery of a sodium hypochlorite wash led to significant decrease in mean 
IGA, EASI and Pruritus VAS scores at 2 and 6 weeks, resulting in improved clinical and quality of 
life assessments for children with active, colonized atopic dermatitis.    
LB818
Analysis of skin disease subtypes for molecular diagnosis and network analysis
M Inkeles,1 R Modlin2,3 and M Pellegrini1 1 MCDB, UCLA, Los Angeles, CA, 2 Division of 
Dermatology, UCLA, Los Angeles, CA and 3 MIMG, UCLA, Los Angeles, CA
Advances in functional genomics and computational biology are driving a major paradigm shift in 
human skin disease research. These approaches can facilitate the identification of disease subtypes, 
which is essential to determine therapy and predict disease course. To identify molecular subtypes 
of disease, we studied leprosy as a model, obtaining gene expression profiles of skin biopsy samples 
from lepromatous leprosy (L-lep), tuberculoid leprosy (T-lep), reversal reaction (RR), and erythema 
nodosum leprosum (ENL). Subtype structure was analyzed with unsupervised hierarchical clustering 
which revealed an overlap between T-lep and RR expression profiles. This structure was validated 
by identifying subtype specific gene signatures and building a Random Forest subtype classifier 
that had 84% and 72% accuracy on testing and training sets, respectively. Although T-lep and 
RR somewhat overlapped as in the clustering, they could be distinguished from L-lep and ENL. 
To identify enriched functional terms associated with each subtype, we performed weighted gene 
correlation network analysis (WGCNA) to identify modules of correlated genes. Two modules were 
significantly associated with L-lep: immunoglobulin and lysosomal pathway, which was supported 
by cell type deconvolution analysis which revealed the presence of B-cells and macrophages in 
L-lep. One module significantly correlated with T-lep contained the gene MMP12, which was 
also identified in the T-lep gene signature. This supports earlier findings that MMPs are found in 
higher abundance in T-lep versus L-lep lesions, providing a further role for tissue remodeling and 
granuloma formation leading to nerve damage in the tuberculoid form of the disease (Teles et al., 
2010). Beyond identifying specific genes and networks associated with leprosy subtypes, this work 
provides now molecular insights into subtype pathogenesis as well as skin disease subclassification.   
LB819
A new moisturizing complex for optimal hydration
N Verrecchia, I Bonnet and V Cenizo BASF Beauty Creations Beauty Care Solutions France 
SAS, Lyon, France
A new delivery system has been developed. This new technology, based on a molecular mesh of 
natural biopolymers (hyaluronic acid, alginate and pullulan), is loaded with a moisturizing complex 
containing glycerin, serine, trehalose and urea, for offering optimal hydration by acting on two levels. 
On the skin surface, the film-forming properties of the three polymers basically allow to decrease 
the trans-epidermal water loss (TEWL). When combined together, these polymers create a mesh-
work that can entrap and extend the diffusion of the moisturizing ingredients which are gradually 
released into the superficial layers of the epidermis. We demonstrated in vitro better efficiency of 
the loaded technology than the free moisturizing complex. The TEWL test showed the ability to 
limit the evaporation of water on synthetic skin (Vitroskin®) for 48 hours. The measurements of 
dielectric conductivity layer on the human stratum corneum demonstrated that the technology 
significantly increased the moisturization effect. Finally, the technology was clinically tested at 3% 
versus placebo on healthy volunteers. The two studies showed first, an immediate and significant 
improvement of the skin moisturization up to 48 hours after a single application. Secondly, after a 
21 days treatment, the technology demonstrated a significant long term hydration lasting at least 
5 days after the last application.    
LB820
Heme oxygenase stimulation for treatment of dark circles
M Chavan,1 J Litchauer1 and V Cenizo2 1 BASF Beauty Creations Beauty Care Solutions, 
Stony Brook, NY and 2 BASF Beauty Creations Beauty Care Solutions France SAS, Lyon, 
France
Dark circles around the eyes are a complex issue with two main possible causes: the accumulation 
of melanin in the skin around the eyes and the accumulation of heme resulting from blood leakage. 
The free heme produced in this manner is highly cytotoxic, pro-inflammatory and pro-oxidative. The 
effect of Fucus extract on heme oxygenase-1 (HO-1) stimulation activity has been evaluated, and 
its in vitro anti-inflammatory, anti-oxidative and collagen stimulation activity has been measured. 
The HO-1 stimulation activity was first evaluated at gene level by reverse transcriptase- polymerase 
chain reaction targeting specific HO-1 gene, and then followed by western blot in protein level. 
The in vitro anti-inflammatory effect was measured by quantification of IL-8 level. The in vitro 
anti-oxidative activity was measured. Collagen stimulation activity was quantitatively measured by 
the amount of deposited collagen I in the extracellular matrix. Fucus extract was identified to have 
heme oxygenase-1 stimulation activity at both gene and protein level. By stimulating this enzyme, 
it promotes the degradation of toxic heme to its protective catabolites (CO, Ferritin and bilirubin), 
and reduces the source of dark circles. In addition, Fucus extract showed good anti-inflammatory 
efficacy. The strong anti-oxidation property of Fucus extract can reduce eye bags and wrinkles while 
its collagen boosting activity will potentially reduce fine lines and wrinkles.    
LB821
Efficacy of hydroxyphenoxy propionic acid for age spots and skin tone correction
P Moussou,1 O Freis,1 L Danoux1 and V Cenizo2 1 BASF Beauty Creations Beauty Care 
Solutions France SAS, Essey les Nancy, France and 2 BASF Beauty Creations Beauty Care 
Solutions France SAS, Lyon, France
Uneven skin tone and hyperpigmentation disorders - such as age spots (lentigo senilis) - are today 
considered among the first signs of aging while visibly affecting the skin appearance. Reviving the 
luminosity of a youthful-looking skin starts with lightening imperfections as well as uniformizing skin 
complexion. We have identified a new molecule (INCI: Hydroxyphenoxy Propionic Acid) which 
decreases in vitro melanin level produced by melanocytes in a dose dependent manner, with an 
IC50 lower than kojic acid or arbutin, and without any cytotoxicty even at a dose 300 times higher 
than this IC50. This molecule reduced the melanin release by melanocytes without accumulation 
of melanin in the cells. It had no effect on tyrosinase, neither as an inhibitor of the enzyme nor on 
the cellular enzymatic activity, offering an alternative to this pathway already broadly investigated. 
As well as reducing melanogenesis, Hydroxyphenoxy propionic Acid exhibited a photoprotective 
and anti-inflammatory effect on epidermal keratinocytes helping to prevent skin damages caused 
by UVB irradiation. In vivo, the visible and measurable effects on skin were assessed by 3 clinical 
studies on Caucasian and Asian volunteers, after application on the hands, face and forearms, vs 
placebo and/or kojic Acid. From 14 to 56 days of application, it reduced the appearance of age 
spots and increased the evenness of the complexion.    
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A mixture of Casearia sylvestris and Schinus terebinthifolius Raddi natural extracts increase 
the dermal elastic fibers deposition in human skin
JC Lago, D Zimbardi, EC Marcelino, P Araújo, CI Domenico and KF Arroteia Natura 
Innovation and Technology of Products Ltda, Cajamar, Brazil
Two botanical compounds coming from Brazilian vegetal biodiversity, an extract of Casearia sylves-
tris and an extract of Schinus terebinthifolius Raddi were developed with the purpose of improve the 
elastic system of human skin dermis, which undergoes structural and functional modifications with 
the aging process. The pro-elastogenic effect of these compounds was assessed using a combination 
of biochemical assays and in vitro models including cellular culture and ex-vivo human skin model. 
The in vitro results showed that the Schinus terebinthifolius Raddi extract is able to reduce until 
90% of the matrix metalloproteinase-12 (MMP-12) activity, and that the Casearia sylvestris extract 
increases the production of the proteins fibulin-5, fibrillin-1, lysil-oxidase enzyme and tropoelastin 
by human dermal fibroblasts (p<0.05). Due to their complementary mechanism of action, the com-
bination of these compounds increased in 33% the amount of dermal elastic fibers when applied 
on ex-vivo adult women skin fragments (p<0.05). This new natural mixture was also demonstrated 
to be not carcinogenic, mutagenic or cytotoxic and would be useful as an effective component in 
anti-aging and pro-elastogenic cosmetic formulations.    
LB823
Hyperproliferation in psoriasis vs. cancer: Asymmetric vs. symmetric stem cell divisions
S Fong,1,2 G Vitcov,1,2 L Yue,1,2 L Tabernik,1,2 J North,1 S Arron,1,2 A Charruyer1,2 and 
R Ghadially1,2 1 Dermatology, UCSF, San Francisco, CA and 2 Dermatology, VAMC, San 
Francisco, CA
It is not understood why the hyperproliferation in psoriasis is not cancer. We studied differences in 
stem cell (SC) divisions in psoriasis and squamous cell carcinoma. SCs divide in 3 ways: asymmetric 
divisions leading to one SC and one transit amplifying cell and symmetric divisions leading either to 
two SCs or to two transit amplifying cells. Transit amplifying cells undergo symmetric differentiation 
divisions 3-5 times before terminal differentiation. Hyperproliferation in cancer is associated with 
increased symmetric SC divisions, increasing the pool of SCs. We hypothesized that hyperprolifer-
ation in psoriasis is associated with increased asymmetric SC divisions, resulting in no change in 
the SC pool but an increase in transit amplifying cells, compatible with the relatively normal basal 
layer and increased suprabasal compartment observed in psoriasis. SC divisions were assessed 
using Numb and LGN immunofluorescence (both present in the differentiated cell of asymmetric 
divisions). Keratinocytes from psoriasis showed increased asymmetric divisions compared with 
keratinocytes from non-lesional psoriasis and age/gender matched normal skin (50±6% vs. 22±5% 
and 26±3% of total divisions, respectively, n=8, p=0.0002 and 0.007). Keratinocytes from squamous 
cell carcinomas showed increased symmetric divisions compared with keratinocytes from normal 
skin (95±4% vs. 75±3 % of total divisions, n=3, p=0.02). No significant difference in the number 
of SCs in psoriasis vs. non-lesional and normal keratinocytes was detected, using human keratino-
cytes in a xenograft assay, combined with limiting dilution analysis (1 in 13,330 (10,020-17,740) 
vs. 1 in 11,250 (6,620-19,116) and 1 in 7,770 (5,480-11,030). This work indicates that psoriasis is 
associated with increased asymmetric SC divisions, with no change in SC numbers. Understanding 
dysregulation of SC divisions in hyperproliferative disorders will allow selection of appropriate 
agents to manipulate SC divisions for novel therapeutic approaches.    
LB824
Melanoma survival disparity by race and insurance status
K Chiang,1 SM Dawes,4 H Gittleman,3 JS Barnholtz-Sloan3 and J Bordeaux2 1 Case Western 
Reserve School of Medicine, Cleveland, OH, 2 Dermatology, University Hospitals, Cleveland, 
OH, 3 Department of Epidemiology and Biostatistics, Case Western Reserve University, 
Cleveland, OH and 4 Case Western Reserve University, Cleveland, OH
In this study, we explore the effect of race and insurance status on melanoma survival rates while 
controlling for stage of disease at presentation. Data for this study was obtained from the Ohio 
Cancer Incidence Surveillance System (OCISS). We selected for individuals diagnosed with micro-
scopically confirmed cases of cutaneous melanoma between 1996 and 2009 with follow-up to 
2010. Data collected from OCISS registry included age, race, ethnicity, primary payer, stage of 
disease, survival time, and vital status. The 2010 US Census and SEER 13 database were also used 
for demographic data and melanoma incidence rates. Overall survival differences between cohorts 
were calculated using the Kaplan-Meier method with SAS 9.4 software. A total of 31, 957 patients 
were diagnosed with primary cutaneous melanoma (CM) in Ohio from 1996 to 2009. Our patient 
demographic was 90.7% White and 0.5% Black. The primary payer at diagnosis was known for 
67% of the patients—23.7% had private insurance, 19.0% of patients had Medicare and 1.6% 
had Medicaid. We found that the incidence of CM in Ohio is increasing at an average annual rate 
of 7.2% compared to 1.7% for the United States, the vast majority of which can be attributed to 
increases in Stage 0 and Stage 1. Chi-square analysis revealed that patients were more likely to 
present at a later stage of the disease if they were black, have Medicaid, or have Medicare insurance 
(p<0.05). For any given stage, median survival was greater for whites than blacks, especially for 
stage 0 (35 month difference, p=.11) and stage 1 (15 month difference, p=0.01). For stage 0 and 
stage 1, patients with private insurance or no insurance had greater mean survival than patients with 
Medicaid or Medicare (p<0.05). This phenomenon was not present among patients >65yo. Patients 
with no insurance have similar presentation stages and survival rates as patients with insurance.   
LB825
Inherited genetic variants associated with occurrence of multiple primary melanoma
DC Gibbs,1 I Orlow,2 P Kanetsky,3 L Luo,4 A Kricker,5 B Armstrong,5 H Anton-Culver,6 
SB Gruber,7 L Marrett,8 R Gallagher,9 R Zanetti,10 S Rosso,10 T Dwyer,11 E La Pilla,2 C Begg,2 
M Berwick4 and NE Thomas1 1 UNC, Chapel Hill, NC, 2 MSKCC, New York, NY, 3 Moffitt 
Cancer Ctr, Tampa, FL, 4 UNM, Albuquerque, NM, 5 U Sydney, Sydney, NSW, Australia, 6 
UC-Irvine, Los Angeles, CA, 7 USC, Los Angeles, CA, 8 Cancercare, Toronto, ON, Canada, 
9 BC Cancer Research Ctr, Vancouver, BC, Canada, 10 CPO, Torino, Italy and 11 IARC, 
Lyon, France
Recent studies including many genome-wide association studies have identified several putative 
low-penetrance susceptibility loci for melanoma. We sought to validate these associations in the 
Genes, Environment, and Melanoma (GEM) study, a case-control study of multiple primary mel-
anoma (MPM). In this international population-based study, which included 1206 “cases” with 
MPM and 2,469 “controls” with single primary melanoma (SPM) of European ancestry from nine 
geographic regions, we investigated the odds of developing MPM for 47 candidate SNPs from 21 
distinct genetic regions previously reported to be associated with melanoma. ORs and 95%CIs were 
determined using logistic regression adjusting for age, sex, age by sex interaction, and study center. 
We first investigated univariable models and assessed effect measure modification by pigmentary 
phenotype and nevi; then we built multivariable models as appropriate to assess independent effects 
of SNPs. After controlling for pigmentary phenotype, back nevi, other genotypes in the model, 
and an interaction between PARP1 haplotype (rs3219090, rs2695238) and back nevi identified in 
stratified analysis (P=.01; likelihood ratio test), the following SNPs were observed to be significantly 
associated with MPM: TERT rs401681 (P=.005), IRF4 rs12203592 (P=.0004), TYRP1 rs1408799 
(P=.0005), MTAP rs1335510 (P=.0002), TYR rs10830253 (P=.003), and MX2 rs45430 (P=.005). 
In fully adjusted stratified models, PARP1 haplotype AG (P=.01) was significant when <10 back 
nevi were present, while AC (P=.03) was significant when >10 back nevi were present. The results 
confirm the relevance of these genetic loci for the development of melanoma.    
LB826
Genome-wide methylation profiling of cutaneous squamous cell carcinoma reveals novel 
epigenetically regulated genes and pathways
N Mladkova,1,3 V Rakyan,1 C Proby2 and C Harwood1 1 Centre for Cutaneous Research, The 
Blizard Institute, Queen Mary, University of London, London, United Kingdom, 2 Surgery 
and Molecular Oncology, University of Dundee, Dundee, United Kingdom and 3 Population 
and Family Health, Mailman School of Public Health, Columbia University, New York, NY
The purpose of the study was to characterise the methylation profile of Cutaneous squamous cell 
carcinoma (cSCC). cSCC is the second most common form of skin cancer. Its incidence is rising and 
it is associated with significant morbidity, yet its molecular pathogenesis remains largely elusive. 
Epigenetic dysregulation is increasingly recognised as an important contributory mechanism in the 
pathogenesis of various solid cancers, and we compared methylation profiles of 20 cSCCs and 20 
normal skin samples using Illumina Infinium HumanMethylation450 BeadChip and validated the 
results with additional set of paired microdissected cSCC and skin samples subjected to bisulfite 
sequencing using next generation sequencers. We discovered a total of 1085 hyper- and 833 
hypomethylated genes in cSCC (p value<0.01). Functional analysis has identified dysregulation 
of genes involved in immune response (HRH2, CNR2), cell-cell adhesion (claudin 14, NOTCH4) 
and cell development (CASP8, MADD) and LIM domain-containing genes (paxillin, LIM homeobox 
3). KEGG Pathway analysis revealed dysregulation of genes involved in the hematopoietic system 
(Hematopoietic cell lineage, Chronic myeloid leukemia) in addition to WNT, JAK-STAT, ERBB, 
MAPK, MTOR and PPAR signaling pathway that were previously implicated in cSCC oncogenesis. 
Our study describes the role of epigenetic dysregulation in cSCC, and identifies critical molecular 
processes that may be targeted by therapeutic agents in the future.    
LB827
The incidence of herpes zoster in patients with cutaneous lupus erythematosus, dermato-
myositis, and pemphigus vulgaris is increased compared to the average U.S. population
ES Robinson,1,2 J Okawa,1,2 R Feng,3 AS Payne2 and V Werth1,2 1 Veteran Affairs Medical 
Center, Philadelphia, PA, 2 Department of Dermatology, University of Pennsylvania, 
Philadelphia, PA and 3 Department of Biostatistics and Epidemiology, University of 
Pennsylvania, Philadelphia, PA
Herpes zoster is a common condition that causes significant pain and, often, post-herpetic neuralgia. 
The June 6, 2008 Morbidity and Mortality Weekly Report listed the incidence of herpes zoster in 
the United States per 1,000 person-years as 4-5 at age 50, 5-6 at age 60, and 10-11 at or above 80 
years old. The incidence of zoster may be increased in autoimmune diseases, but few studies have 
looked specifically at cutaneous autoimmune diseases. This retrospective chart review examined the 
incidence of zoster in patients with cutaneous lupus erythematosus (CLE) (n=105), dermatomyositis 
(DM) (n=66), and pemphigus vulgaris (PV) (n=55) seen in the practices of two University of Penn-
sylvania dermatologists. All records of CLE, DM, and PV patients with at least one visit in the six 
months prior to September 30th, 2013 were reviewed. Patients with a known history of zoster prior 
to the start of the electronic medical records were excluded as were patients whose date of zoster 
was unknown. The incidence rate of zoster was 23 per 1,000 person-years for CLE, 54 per 1,000 
person-years for DM, and 14 per 1,000 person-years for PV. The mean age (standard deviation) of 
each group was: 46.2 (14.1) for CLE, 55.9 (14.2) for DM, and 56.1 (13.8) for PV. Fourteen of the 
sixteen patients who had zoster were on immunosuppressive medications at the time of the zoster 
episode. This study found an increased incidence of zoster in patients with CLE, DM, and PV in 
the Philadelphia region compared to the average U.S. population.    
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p21 gene silencing promotes growth of human dermal papilla cells in vitro
J Yi,1 L Zhang,2 Y Cheng,1 C Hu,1 S Gao1 and G Zhang1,3 1 Department of Dermatology, 
Fourth Hospital, Hebei Medical University, Shijiazhuang, China, 2 Department of 
Interventional Radiology and Vascular Surgery, Peking University Third Hospital, Beijing, 
China and 3 Hebei Provincial Institute of Dermatology, Provincial Academy of Medical 
Science, Shijiazhuang, China
Human dermal papilla cells (DPCs) play a significant role in hair follicles formation and hair growth. 
It is known that early-passaged DPCs can induce hair growth in vitro, however, this property is 
gradually lost upon further culturing. The mechanism of the phenomenon might be cell senescence 
mediated by the cyclin-dependent kinase inhibitor (CDKIs) which contains p21. In this study, the 
correlation between the biological property of DPCs and p21 was analyzed, and proliferation effect 
of DPCs was observed via transfection inhibition of p21. The experimental DPCs were treated with 
Ard5-HK-1p2 shRNA and Ard5-CDKN1A-1p2 shRNA, normal DPCs without any intervention served 
as control. Electron microscopy, MTT measurement, flow cytometry, immunocytochemistry and 
PCR were used. The results showed that: (1) G1-phase arrest, apoptosis-promoting effect and more 
expression of P21 protein were detected in the 10th-passaged normal DPCs when these cells lost the 
multilayer aggregative growth-tendency and the proliferation ability; (2) After Ard5-CDKN1A-1p2 
shRNA transfection, less expression of P21 protein and p21 mRNA were found, indicating successful 
p21 gene transcriptional repression; (3) Much more karyolobism, faster proliferation rate, lower 
proportion of G1-phase, apoptosis-promoting effect were found in DPCs with Ard5- CDKN1A-1p2 
shRNA. Our results suggested p21 is involved in regulating the DPCs senescence, which leads the 
DPCs to growth arrest and cell-cycle arrest, and inhibits the apoptosis of the DPCs in vitro. Transcrip-
tional repression of p21 may provide a new method with promoting the proliferation of DPCs in vitro.   
LB829
The x-ray crystal structure of the N-terminus of human profilaggrin
CG Bunick Dermatology, Yale University, New Haven, CT
Using x-ray crystallography, I determined the 2.2 Angstrom resolution structure of the N-termi-
nal S100 fused-type calcium binding domain of human profilaggrin bound to calcium ions. This 
domain contains a four alpha-helix bundle as classically seen in EF-hand domains. Analysis of the 
interhelical angles within the EF-hand domain demonstrates unique helical orientations compared 
to other S100 family proteins. The x-ray structure reveals a molecular basis for dimerization of 
profilaggrin, which is supported by gel filtration and light scattering experiments. The molecular 
surface of profilaggrin exhibits a hydrophobic pocket, which in the crystal structure contains a 
polyethylene glycol molecule. The bound molecule alters the conformation of the inter-EF-hand 
linker. The molecular features of the hydrophobic pocket suggest a putative role for this pocket in 
modulating epidermal development or differentiation through protein-protein signaling. Therefore, 
the profilaggrin crystal structure potentially enables the development of novel topical therapeutics 
affecting the skin barrier using structure-based drug design.    
LB830
PTH-CBD, a long-acting parathyroid hormone analog, prevents alopecia after cyclophos-
phamide administration in mice
R Katikaneni,1 R Goforth,2 T Ponnapakkam1 and RC Gensure1 1 Pediatrics, Children’s 
Hospital at Montefiore, Bronx, NY and 2 BiologicsMD, Fayetteville, AR
PTH-CBD is a hybrid protein of PTH(1-33) and a bacterial collagen binding domain designed to 
accumulate in collagen rich areas such as skin. We have previously shown that PTH-CBD can 
prevent chemotherapy-induced osteoporosis in depilated and non-depilated mouse models. PTH-
CBD increases the number of anagen-phase hair follicles and reverses dystrophic changes. We now 
investigate the time course of this response in a non-depilated model, through timed histological 
analysis in a mouse model with chemotherapy-induced alopecia. 8 week old C57BL/6 mice were 
treated with cyclophosphamide (50 mg/kg/wk IP x 3 weeks), cyclophosphamide plus PTH-CBD 
(320 mcg/kg SQ x1), or vehicle alone. Animals were photographed and sacrificed at baseline, 1 
month, 2 months, or 3 months to provide skin samples throughout the expected time of the treatment 
response. Grey scale analysis of photographs confirm that cyclophosphamide treatment causes 
alopecia, which was statistically significant after 2 months (mean intensity 218.4+/-1.9 no chemo 
vs 199.6+/-8.6 chemo, p<0.05). PTH-CBD therapy in cyclophosphamide-treated mice prevented 
this alopecia (mean intensity 218.9+/-2.8 PTH-CBD + Chemo vs 199.6+/-8.6 chemo, p<0.05, such 
that there was no difference between animals which did not receive chemotherapy. Skin samples 
will be processed for assessment of hair follicle dystrophy and follicular number (per HPF), as well 
as immunohistochemistry staining for the hair cycle inducer beta-catenin. Together, these data will 
provide confirmation of the effects of cyclophosphamide on hair follicles to cause alopecia, and 
will provide information of the time course of response to PTH-CBD to clarify how this compound 
prevents cyclophosphamide-induced alopecia.    
LB831
Vitamin D promotes dendritic cell-mediated host defense responses
S Andrea1,2 and M Fabri1,2 1 Dermatology, University of Cologne, Cologne, Germany and 2 
Center for Molecular Medicine, University of Cologne, Cologne, Germany
As part of the human host response to infection in epithelial tissues, dendritic cells (DCs) induce an 
inflammatory cytokine response and promote differentiation of T helper (Th) cell subsets, specifically 
Th1, Th17 and Th22 cells. Studies in the background of autoimmunity suggested that vitamin D 
treatment of human DCs elicits IL-10-secreting, thus Th2-promoting, but not IL-12-secreting, thus 
Th1-promoting DC phenotypes. However, the effect of vitamin D on DCs regarding their ability to 
secrete central inflammatory host defense cytokines and to promote differentiation of IL-17- and 
IL-22-producing T cells remains unclear. Here, we investigated the effect of vitamin D treatment 
of human cytokine-derived DCs in this context. Vitamin D treatment of DCs markedly enhanced 
their ability to secrete TNF-α, IL-6, IL-1β and IL-23. Moreover, vitamin D-treated DCs as compared 
to their not-vitamin D-treated counterparts comparably regulated Th1 and Th17 differentiation, 
but were significantly more potent in driving differentiation of IL-22-producing T cells. Finally, we 
found that the differentiation of IL-22-producing T cells mediated by vitamin D-treated DCs was 
dependent on TNF-α and IL-6. In summary, our study suggests an unexpected role of vitamin D in 
promoting key aspects of DC-mediated epithelial host defense.    
LB832
Proteomics profiling suggests molecular similarities between aging and systemic sclerosis 
dermal fibroblasts
V Dumit,1,2 V Küttner,2,3 S Piera-Velazquez,4 S Jimenez,4 L Bruckner-Tuderman,3 J Uitto4 
and J Dengjel2,3 1 FRIAS, University of Freiburg, Freiburg, Germany, 2 Center for Biological 
Systems Analysis, Freiburg, Germany, 3 Department of Dermatology, University Medical 
Center Freiburg, Freiburg, Germany and 4 Department of Dermatology and Cutaneous 
Biology, Jefferson Medical College Philadelphia, Philadelphia, PA
Matrix accumulation can be observed in fibrotic disorders, such as systemic sclerosis (SSc). It is also 
known that with age, the level of insoluble extracellular matrix increases leading to loss of elasticity 
in a number of tissues. Thought quantitative proteomics we have characterized the phenotype of skin 
fibroblasts from healthy donors of various ages and from patients suffering from systemic sclerosis. 
Our results demonstrate that proteins involved in DNA and RNA processing decrease with age and 
in SSc. Particularly, mini-chromosome maintenance (MCM) proteins, which constitute the replica-
tive helicase complex, are less abundant with age and SSc. Additionally, MCM proteins exhibit an 
altered subcellular distribution in SSc cells. We show that lower levels of MCM7 are causative for 
reduced cell proliferation, lower autophagic capacity and higher protein expression phenotypes 
of aging and SSc cells. Therefore, SSc fibroblasts exhibit intrinsic characteristics of fibroblasts from 
aged skin at the proteome level.    
LB833
Novel and recurrent FERMT1 mutations in Iranian families with the Kindler syndrome
L Youssefian,1,2 H Vahidnezhad,1,2,3 Q Li,2 MR Barzegar,4 S Sotoudeh,1 A Yazdanfar,5 
A Kajbafzadeh,6 F Agha-Hosseini,7 M Tabrizi1 and J Uitto2 1 Medical Genetics, Tehran 
University of Medical Sciences, Tehran, Islamic Republic of Iran, 2 Department of 
Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, 3 
Biotechnology Research Center, Department of Molecular Medicine, Pasteur Institute of Iran, 
Tehran, Islamic Republic of Iran, 4 Skin Research Center, Shohad e Tajrish Hospital, Shahid 
Behesti University of Medical Sciences, Tehran, Islamic Republic of Iran, 5 Department of 
Dermatology, Hamedan University of Medical Sciences, Hamedan, Islamic Republic of Iran, 
6 Pediatric Urology Research Center, Pediatric Center of Excellence, Tehran University of 
Medical Sciences, Tehran, Islamic Republic of Iran and 7 Department of Oral Medicine, 
Dental Research Center Dentistry School, Tehran University of Medical Sciences, Tehran, 
Islamic Republic of Iran
The Kindler syndrome (KS), a rare autosomal recessive genodermatosis, is characterized by diffuse 
poikiloderma, cutaneous atrophy, acrokeratosis, trauma-induced blisters and photosensitivity. Muta-
tions have been previously disclosed in the FERMT1 gene which encodes kindlin-1, a component 
of keratinocyte focal adhesions. The incidence of KS is expected to be high in Iran due to frequent 
consanguineous marriages. We identified a total of 13 Iranian families with KS, including several 
with multiple affected individuals. Pedigree analysis of all these families revealed high degree of 
consanguinity. The patients demonstrated characteristic clinical features while the parents, obligate 
heterozygous carriers, were clinically unaffected, consistent with autosomal recessive inheritance. 
Mutation analysis of FERMT1 by amplification of all 15 exons and flanking intronic sequences, 
followed by bidirectional sequencing, revealed homozygous nonsense mutations, both recurrent 
and novel, including p.R328X and p.W205X as well as p.Y392X and p.Y461X, respectively. The 
previously unpublished mutations in the FERMT1 gene expand the spectrum of mutations under-
lying KS. The identified mutation database forms the basis to confirm the clinical diagnosis by 
genetic testing and to identify heterozygous carriers, coupled with genetic counseling to reduce 
the burden of KS in Iran.    
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Infantile systemic hyalinosis in an Iranian family: A novel mutation in the ANTXR2 gene
H Vahidnezhad,1,2,3 L Youssefian,2,3 V Ziaee,2 Q Li,3 S Sotoudeh2 and J Uitto3 1 
Biotechnology Research Center, Department of Molecular Medicine, Pasteur Institute of Iran, 
Tehran, Islamic Republic of Iran, 2 Medical Genetics, Pediatric Rheumatology, Dermatology, 
Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran and 3 Department of 
Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA
Infantile systemic hyalinosis (ISH) (OMIM 228600) is a rare autosomal recessive inherited disorder 
characterized by multiple subcutaneous skin nodules, livid red hyperpigmentation, painful and 
swollen joint contractures and hyaline deposition together with gingival hypertrophy and thickened 
skin. Affected children are susceptible to infections and/or intractable diarrhea due to protein-los-
ing enteropathy and many die in infancy from resulting multisystem failure. Less than 20 affected 
individuals have been reported so far. ISH is caused by mutations in the ANTXR2 gene which is 
involved in extracellular matrix homeostasis. This gene encodes a 55 kDa type I transmembrane 
protein known as capillary morphogenesis protein 2 (CMG2). The gene is expressed in all tissues 
except the brain, consistent with development of normal intelligence in patients. Sixty percent of 
patients carry frameshift mutations at a mutational hotspot in exon 13. In this study we conducted 
a molecular analysis of an affected child with ISH in a family from Azerbaijan of Iran. The patient 
showed disease manifestations at birth and he has a healthy dizygotic twin sibling. Other symp-
toms include painful swollen joint contractures, thick skin, hyperhidrosis, growth retardation and 
hyperpigmentation. Extensive family history was documented and DNA was extracted from patient 
blood sample. PCR amplification of all 17 exons and flanking intronic regions of the ANTXR2 gene 
was performed. PCR products from the patient were bi-directionally sequenced and analyzed. 
The patient harbored a novel homozygous mutation of c.1069delG in exon 13. In conclusion, we 
present a novel mutation in the ANTXR2 gene from Iran which expands the existing spectrum of 
mutations in the ISH database.    
LB835
Differences in keratinocyte colony formation in response to substrate stiffness
H Zarkoob,1 JC Selby,2 K Messingham,2 JA Fairley2 and E Sander1 1 Biomedical Engineering, 
University of Iowa, Iowa City, IA and 2 Dermatology, University of Iowa, Iowa City, IA
Keratinocytes differentiate and stratify to form a mechanically functional epidermis. This function-
ality is dependent on the composition and organization of anchoring junctions and cytoskeletal 
proteins. Mechanical cues may play an important role in shaping epidermal sheet formation and 
mechanical stability. In this study, the effects of substrate stiffness on keratinocyte colony formation 
were investigated. Collagen coated polyacrylamide (PA) gels embedded with fluorescent beads were 
prepared with stiffnesses of 1.2 kPa (soft) and 8.6 kPa (stiff). Keratinocytes were cultured on the 
gels at a density of 125,000 cells/cm2. The cells were allowed to attach for 3 hours and to reach 
equilibrium in a temperature-controlled chamber. After 3 hours, the Ca2+ of medium was changed 
from 0.09 mM (L Ca2+) to 1.2 mM (H Ca2+) in order to induce colony formation. Time-lapse DIC 
and fluorescent images were acquired every 5 minutes over a 48 hour period so that substrate 
deformation, cell migration, and colony formation could be observed and quantified. In a separate 
set of experiments, samples were labeled for pan cytokeratin and actin to visualize the cytoskeleton. 
Samples were fixed at t = 0, 15 min, 1h, 4h, 24h,and 48h after changing to H Ca2+ medium. A 
parallel set of samples subjected to L Ca2+ were prepared at equivalent time points. Keratinocytes 
were highly mobile over 48 hours on both gels, both individually and collectively as colonies. At 
all time points substantially larger displacements were observed on soft compared to stiff gels (e.g., 
maximum bead displacements at 24 hours were ~230 um and ~ 7 um, respectively). In addition, 
cell migration appeared more directed and colony formation was faster on soft compared to stiff 
gels. Differences in the organization of cytoskeletal keratin and actin were also apparent between 
cells culture on soft and stiff PA gels and between cells cultured in L Ca2+ and H Ca2+ medium.   
LB836
Recurrence and risk of melanoma related to biopsied dysplastic nevi: Do types of histologic 
margins and biopsy method matter?
S Varada,1 J Park,2 A O’Donnell3 and C Kim4 1 Jefferson Medical College, Philadelphia, PA, 
2 University of Illinois College of Medicine, Chicago, IL, 3 Epidemiology, Centers for Disease 
Control, Atlanta, GA and 4 Dermatology, Beth Israel Deaconess Medical Center, Boston, MA
Punch and scoop shave techniques are often used to biopsy dysplastic nevi (DN) and frequently 
produce positive histologic margins. However management of DN with positive margins is an area 
with little guidance, although recent studies have suggested that only nevi exceeding a certain 
degree of atypia require re-excision. This study aimed to determine if the same can be said of nevi 
removed with a certain biopsy margin or biopsy method. A retrospective review assessed 593 nevi 
observed after biopsy for recurrence and 148 nevi re-excised after biopsy for residual nevi, consid-
ering both the margin type: clear, grossly positive (GP), or narrowly excised (NE), and the biopsy 
method: shave, punch, or elliptical excision. GP was defined as numerous cells at the margin; NE 
was defined as a microscopic focus of cells within 1 mm of the margin. Of the 593 observed biopsy 
sites, 589 remained clear, while 2 exhibited recurrences, although none were of greater atypia 
than the original nevi. 2 had been removed with GP margins (p=0.012) and 2 by shave biopsy 
(p=0.038). Of the 148 re-excised biopsy sites, 112 remained clear, while 36 exhibited residual nevi, 
although none were of greater atypia than the original nevi. 29 had been removed with GP margins 
(p=0.0007), 5 with NE margins (p=0.0292), and 2 with clear margins (p=0.0671); 4 were removed 
by shave, 22 by punch, and 10 by elliptical excision, although any associations between biopsy 
method and residual nevi were not statistically significant. As neither recurrent nevi nor residual 
lesions exceeded the atypia of their original lesions, these data suggest that re-excision of any DN 
to prevent malignant recurrence is unnecessary. However, GP margins seem to pose a higher risk 
of both incomplete lesion removal and nevus recurrence after biopsy, and may warrant re-excision 
if only to prevent recurrence in a patient for whom follow-up is difficult.    
LB837
Preclinical study to develop smoothened inhibitor resistant basal cell carcinomas in mice
A Lee,1,2 R Whitson,1 M Rezaee,1,2 A Chanana,1,2 E Epstein,2 A Oro1 and JY Tang1 1 
Dermatology, Stanford University, Stanford, CA and 2 Children’s Hospital Oakland Research 
Institute, Oakland, CA
The aberrant upregulation of the Hedgehog (HH) signaling pathway is the primary driver of Basal 
Cell Carcinomas (BCC). Drugs that inhibit the HH pathway typically antagonize the Smoothened 
protein (SMO), a key transducer of HH signaling. In humans, cases of emerging resistance to SMO 
inhibitors (SMOi) after prolonged treatment have been reported. We generated a preclinical model of 
SMOi resistant BCCs in mice to understand the histologic and genomic changes that define acquired 
drug resistance. Single cell suspensions of BCC tumor cells were generated from Ptch+/- K14Cre-ER 
p53fl/fl mice and injected subcutaneously into NOD/SCID immunodeficient mice. Visible BCCs 
were observed in 3-4 weeks and mice were treated with XL-139 via oral gavage (25mg/kg, 2x per 
week, from BMS) until tumor volumes shrank to 50% of baseline volume. Drug was stopped when 
tumors returned to baseline size, and mice were intermittently treated with XL-139 for 3-12 cycles. 
Resistant BCCs developed after a mean of 106.23 days (range: 25-242, SD 72.14) and resistance 
was confirmed when tumors continued to grow after doubling drug dosage. We enrolled 101 BCCs 
(N= 60 mice) to develop 28 resistant and 73 sensitive BCCs. Resistant BCCs had 2 histological 
subtypes: nodular BCC-like (45%) and spindle-cell like morphology (55%) in contrast to SMOi 
sensitive BCCs that all retained nodular BCC histology (P<0.001). RNA-sequencing with 430X 
coverage showed that the top activated pathway was the HH signaling pathway in resistant BCCs 
compared to sensitive BCCs and confirmed the expression of higher Gli mRNA levels (P<0.01) . In 
conclusion, we report a preclinical model of SMOi resistant BCCs where the HH pathway is still 
maintained during acquired drug resistance. This model can be used to screen second line SMOi 
or new drugs that target proteins downstream of SMO such as arsenic trioxide (FDA approved for 
promyelocytic leukemia) and itraconazole (an antifungal).    
LB838
Phase 2 study of efficacy and safety of SB204 in the treatment of acne vulgaris
J Rico,1 J Quiring,2 S Hollenbach,1 C Enloe1 and N Stasko1 1 Novan Therapeutics, Durham, 
NC and 2 QST Consultations, Allendale, MI
Results from a Phase 2, multi-center, randomized, double-blinded, vehicle-controlled study com-
paring the efficacy and safety of 2 concentrations of topical nitric oxide-releasing gel, SB204, to 
Vehicle Gel in subjects with acne vulgaris are reported. SB204 contains NVN1000, a new molecular 
entity with immunomodulatory and antimicrobial activity that inhibits lipogenesis. Subjects who met 
the study entry criteria were enrolled and randomized to receive twice daily topical applications 
of SB204 1%, SB204 4%, or Vehicle for 12 weeks. Endpoints included the absolute change in 
non-inflammatory lesion counts (1° endpoint), inflammatory lesion counts and Investigator Global 
Assessment (IGA) (2° endpoints) at end of treatment. 153 subjects were randomized and 129 com-
pleted the study. In the intent to treat (ITT) analysis, the mean absolute change from baseline for 
non-inflammatory lesions at the end of treatment was -0.30 for Vehicle, -12.1* for SB204 1%, and 
-11.0* for SB204 4% (* p≤0.05 compared to Vehicle). The mean absolute change from baseline 
in inflammatory lesions was -9.30 for Vehicle, -13.7 for SB204 1% and -15.5* for SB204 4% with 
a median reduction for inflammatory lesions of 62%. Statistically significant reductions in both 
inflammatory and non-inflammatory lesions were observed as early as week 4 (p≤0.05). There 
was a decrease in disease severity following treatment with SB204; no significant differences were 
measured among treatment groups for the dichotomized IGA requiring a two-grade change and 
IGA of “clear” or “almost clear”. Both SB204 1% and 4% were safe and well tolerated with no 
serious adverse events reported. The adverse event and laboratory profile were similar in SB204 
and Vehicle treated subjects. Exploratory measurements of sebum produced on the forehead were 
also collected in a subset of subjects (n=70). At week 12, subjects treated with SB204 had 80% less 
sebum on their skin surface than those treated with Vehicle. This study supports further development 
of SB204 for acne vulgaris.    
LB839
Equal retinoic acid-efficacy and lower irritation accomplished by a novel encapsulated ret-
inol formulation
V Vega,1 E Makino,1 RC Mehta,1 L Colvan,1 MA Bachelor,2 A Armento2 and TJ Stephens3 1 
R&D, SkinMedica, Carlsbad, CA, 2 MatTek Co, Ashland, MA and 3 Thomas J. Stephens & 
Associates, Colorado Springs, CO
Retinoids are the gold standard for the treatment of photoaged skin, although they are associated 
irritation leading to decreased product acceptance/compliance. Usage of esters or pro-drugs of 
retinoic acid (RA) and sustained release delivery systems had been used to minimize irritation. 
Degradation, decreased stability, encapsulation efficiency and dermal delivery are some of the 
technical difficulties associated to these approaches. In an attempt to minimize retinol-irritation 
without compromising efficacy retinol was encapsulated in solid lipid particles (diameter>0.2mi-
crom) along with phytoene and phytofluene. Free anti-oxidant and anti-inflammatory ingredients 
(Magnolia grandiflora and Dunaliella salina extracts, niacinamide and palmitoyl tripeptide-8) 
were added. Efficacy and irritation were evaluated using in vitro and clinical approaches using 
RA (0.05%) as positive control. Full-thickness human skin equivalent tissue assays showed equal 
expression of efficacy markers between RA and ReC; while irritation (HBEGF) and inflammation 
(IL1B) were significantly lower in ReC-treated tissues. Clinical testing was accomplished by two 
randomized, double-blinded, half-face comparison studies. No significant differences at fine lines/
wrinkles, tactile roughness, mottled pigmentation, overall photodamage and global improvements 
were observed (12 weeks); while erythema, scaling/dryness and peeling were consistently lower 
in the ReC treated side. These results suggest that ReC delivers similar efficacy to RA (10:1 ratio), 
while minimizing acute irritation.    
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LB840
Dermatology learning tools for first year medical students
P Bennett,1 LN Boyers,2 A Schultz,3 P Stephens1 and C Dunnick1,3 1 University of Colorado 
School of Medicine, Aurora, CO, 2 Georgetown University School of Medicine, Washington, 
DC and 3 Department of Dermatology, Denver Department of Veterans Affairs, Eastern 
Colorado Health Care System, Denver, CO
At the University of Colorado School of Medicine, the first-year medical student (MS) curriculum 
utilizes various methodologies to optimize learning and understanding of dermatologic conditions 
and treatments. The core lecture series is supplemented with a tactile learning session, tomato 
biopsy lab, and skin exam videos conducted in small groups. MS assessments of these supplemental 
learning modalities were obtained using a 15 question survey. A total of 126 surveys were completed 
(response rate 80%). The tactile learning tool received the highest ratings across the board. 79% 
of respondents were ‘very satisfied’ and ‘satisfied’ (VS/S) with tactile learning as a tool for learning 
how to describe primary skin lesions, 76% ‘strongly agree’ and ‘agree’ (SA/A) that their confidence 
describing lesions improved, and 71% thought it was ‘very important’ and ‘important’ (VI/I) as an 
educational tool. With regard to the tomato biopsy lab, 82% were VS/S with it as an introduction 
to the biopsy procedure, 64% SA/A that it improved their confidence to perform a biopsy, and 59% 
thought it was VI/I as an educational tool. Lastly, 63% were VS/S with the videos as an educational 
tool for patient care, but the majority did not feel it was VI/I to their education and improving 
confidence to perform skin exams. Hence, it can be determined that the tactile learning tool and 
tomato biopsy lab were viewed more favorably in terms of their value as learning tools compared 
to the skin exam videos. We hypothesize that the interactive and hands-on nature of the tactile 
learning tool and tomato biopsy lab resulted in the higher rating. One student commented that a 3D 
learning tool was unique in a learning environment that utilizes mostly 2D technology. Limitations 
to this study include inability to control for small group variability due to the resident leader and 
students who composed the groups.    
LB841
The autophagy genes ULK1/ULK2 negatively regulate autophagy induction by modified vac-
cinia virus Ankara and are involved in promoting viral replication
W Wang,1 C Serna-Tamayo,1 P Dai,1,2 T Lindsten,3 S Shuman2 and L Deng1,4 1 Dermatology 
Service/Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 
2 Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, 
3 Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY and 4 
Department of Dermatology, Weill Cornell Medical College, New York, NY
Autophagy is a catabolic cellular response to nutrient starvation and stress through sequestration 
and degradation of cellular contents, via the formation of autophagosomes and autolysosomes. 
Autophagy plays important roles in host antiviral innate and adaptive immune responses. The highly 
attenuated modified vaccinia virus Ankara (MVA) has a 31-kb deletion of the parental genome, 
and is currently being developed as a vaccine vector. We recently reported that MVA-induction 
of type I interferon requires the cytosolic DNA sensor cGAS (cyclic GMP-AMP synthase) and its 
adaptor STING (stimulator of interferon genes). Here we show that infection of immortalized mouse 
embryo fibroblasts (MEFs) with MVA, but not with live wild-type vaccinia (WT VACV), triggered 
autophagy induction. MVA-induced autophagy was dependent on STING and it was diminished 
in ATG5 knock-out MEFs. By contrast, MVA-induced LC3-lipidation (a hallmark of autophagy) 
was enhanced in the absence of ULK1/ULK2 (uncoordinated 51-like kinase 1 and 2) and ATG9a. 
ULK1/ULK2, the mammalian homologs of yeast ATG1, are essential kinases involved in autophagy 
initiation in response to nutrient starvation or mTOR inhibition. The role of ULK1/ULK2 in vaccinia 
replication was unknown. One-step growth analysis showed that MVA titers were increased by 
100-fold in WT MEFs but were only increased by 15-fold in ULK1/ULK2-deficient MEFs. Western 
blot analysis showed that STING levels were increased in ULK1/ULK2-deficent MEFs compared 
with WT controls. We conclude that MVA-induces ATG5-dependent non-canonical autophagy and 
ULK1/ULK2 negatively regulate MVA-induced autophagy and promote MVA replication possibly 
through down-regulating STING protein.    
LB842
A critical role for BMP antagonists in crosstalk between RAS/MAPK and BMP signaling in 
the skin
S Espanola, S Krishnaswami, S Kumar and BD Yu UCSD School of Medicine, La Jolla, CA
A wide-range of human skin conditions demonstrate aberrant changes in RAS/RAF signaling, includ-
ing cancer, congenital disease, and inflammatory conditions. Congenital defects in BRAF cause 
epidermal, craniofacial and cardiac defects. In a recently developed mouse model, we found that 
congenital activation of BRAF (K14-cre; Braf) leads to the specific loss of spinous and granular 
keratinocytes. Using this model, we have conducted a small drug screen on skin explants utilizing 
such inhibitors as PLX4720 (BRAF), DAPT (Notch), IWP2 (WNT) and DMH1 (BMP) to identify 
pathways involved in specifying the two missing cell types in BRAF mutants. This study demon-
strates that rescue of spinous and granular keratinocyte differentiation is inhibited in the presence 
of DMH1. Treatment of normal human epidermal keratinocytes (NHEK) and mouse tail epidermis 
with DMH1 further highlights an effect of this pathway on specification of epidermal identities. 
Gene expression profiles from RNA-seq of BRAF-activated epidermis demonstrates upregulation of 
several BMP antagonists, many of which are also induced in response to lentiviral introduction of 
BRAF into human keratinocytes. These findings suggest that activated BRAF opposes BMP signaling 
in the skin via its regulation of secreted antagonists.    
LB843
Quality of adverse event reporting for persistent sexual dysfunction after oral finasteride 
for androgenic alopecia
I Aslam,1 T Kiguradze,1 W Temps,1 G Micali,3 DP West1 and SM Belknap1,2 1 Dermatology, 
Northwestern University, Chicago, IL, 2 Medicine, Northwestern University, Chicago, IL and 
3 Dermatology, University of Catania, Catania, Italy
Persistent sexual dysfunction (PSD) is increasingly described as an adverse event (AE) for finasteride 
(F) in the treatment of androgenic alopecia (AGA. We evaluated quality of AE reporting for PSD in 
clinical trials of F in AGA. METHODS: Within MEDLINE and ClinicalTrials.gov, we identified 34 
reports of F trials in adult men with AGA. Ioannidis criteria were applied for safety reporting in order 
to classify quality of AE reporting as adequate, partially adequate, or inadequate. Safety reporting 
was classified as adequate if it provided rates of affected individuals for each specific AE along with 
a detailed description of the severity. Duration of safety evaluation was determined for each trial 
and we assessed generalizability to an actual patient population in a large urban academic center 
database.RESULTS: None of the reports met criteria for adequate safety reporting, 18 were partially 
adequate, 15 were inadequate, and 1 reported no AEs. Median duration of drug safety evaluation 
was 1 yr (range:1 mo -10 yrs). Common inclusion criteria were “excellent health” or “free of any 
chronic disease” and 10 (29%) trials excluded patients with conditions known to increase the risk 
of sexual dysfunction (SD). Comparison with a large cohort of actual patients, determined that the 
trial inclusion/exclusion criteria excludes 78% of patients receiving F for AGA.18 (53%) trials had 
>/= 1 author(s) declaring conflict of interest and19 (56%) disclosing funding from a F pharmaceu-
tical manufacturer. CONCLUSIONS: Available safety information for F in AGA is insufficient to 
determine risk of PSD . Exclusion from clinical trials of subjects with risk factors for SD also limits 
the external validity of published reports. The poor quality of safety information on PSD after use 
of F in AGA raises the need for enhanced education and monitoring for PSD by health providers as 
well as patients. Supported, in part, by the Post-Finasteride Syndrome Foundation.
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